(CRDF) – Globe Newswire
-
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
-
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
-
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
-
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
-
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
Back to CRDF Stock Lookup
